uBiome Appoints Dr. Suzanne Devkota, PhD, Cedars-Sinai Researcher and Professor, to its Scientific Advisory Board

Share Article

The leader in microbial genomics appoints accomplished microbiologist to its board of scientific advisors.

“uBiome continues to grow and evolve as leader in the microbiome space. I am delighted to join the SAB and look forward to interacting with the team during this exciting time.” - Dr. Devkota, PhD

uBiome, the leader in microbial genomics, announces the addition of Dr. Suzanne Devkota, PhD, Assistant Professor in the Department of Medicine at University of California Los Angeles and at Cedars-Sinai Medical Center to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Devkota will bring to uBiome a scientific background in the dynamic relationship between the gut microbiome and diet. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Devkota’s scientific insights have helped to explain why instances of IBD, diabetes, and food allergies have increased over the past several decades,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are delighted to welcome Dr. Devkota to the uBiome Scientific Advisory Board.”

Dr. Devkota serves as the Director of Microbiome Research at the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, where she has her lab, the Devkota Lab. She investigates the possibility to re-shape human microbiomes therapeutically through the diet to serve as a real and sustainable approach for future medical care. She is also a Science Fellow at Branco Weiss-Society and member of the California Nanosystems Institute. She completed her PhD at the University of Chicago and postdoctoral research at Harvard Medical School Joslin Diabetes Center. Her goal is to add a powerful new dimension to diagnosis and treatment through a better understanding of gut microbial contributions to disease.

About joining uBiome's Scientific Advisory Board, Dr. Devkota said, “uBiome continues to grow and evolve as leader in the microbiome space. I am delighted to join the SAB and look forward to interacting with the team during this exciting time.”

In addition to Dr. Devkota, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
Visit website